Filing Details
Spero Therapeutics, Inc. (NASDAQ:SPRO) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:SPRO
Spero Therapeutics, Inc. (SPRO) Reports Material Event to SEC
Filing Details Spero Therapeutics, Inc. (NASDAQ:SPRO) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market Context…
Market Context
Spero Therapeutics, Inc.'s stock currently trades at $1.70 with a market capitalization of $132.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Spero Therapeutics, Inc.'s stock.
All SEC filings for Spero Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SPRO Stock Page
Frequently Asked Questions
Where can I read SPRO's SEC filings?
Browse all filings on our SPRO SEC filings page.
What types of SEC filings does Spero Therapeutics, Inc. file?
Public companies like Spero Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.